|
Bravo-Perez C, Cifuentes-Riquelme R, Padilla J, de la Morena-Barrio ME, Ortuno FJ, Garrido-Rodriguez P, Amigo ML, Heras I, Vicente V, Lozano ML, Teruel-Montoya R, de la Morena-Barrio B, Corral J. The whole is greater than the sum of its parts: Long-read sequencing for solving clinical problems in haematology. J Cell Mol Med. 2024 Feb;28(3):e17961. doi: 10.1111/jcmm.17961. Epub 2024 Jan 23. No abstract available. PubMed PMID: 38260950; PubMed Central PMCID: PMC10844759.
AÑO: 2024; IF: 4.3
|
38260950
|
Bravo-Perez C, Blanco A, Revilla N, Cobos J, Salgado-Parente A, Asenjo S, Mendez R, Marti-Bonmati L, Bonanad S, Albillos JC, Castro N, Marcellini S, Lopez Sala P, Lasa M, Bastida JM, Infante MS, Corral MA, Pagan J, Llamas P, Rodriguez-Sevilla JJ, Rodriguez-Alen A, Sevivas TS, Morello D, Villar CG, Lojo S, Marco A, Simioni P, Vicente V, Lozano ML, de la Morena-Barrio ME, Garcia-Santos JM, Corral J; IVC Agenesis Study Group. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study. Lancet Haematol. 2024 Aug;11(8):e606-e616. doi: 10.1016/S2352-3026(24)00138-8. Epub 2024 Jun 12. PubMed PMID: 38878784.
AÑO: 2024; IF: 15.4
|
|
Sanchez Canovas M, Garcia Torralba E, Blaya Boluda N, Sanchez Saura A, Puche Palao G, Sanchez Fuentes A, Martinez Montesinos L, Poveda Ganga C, Garcia Tomas L, Bayona Jimenez J, Cos Zapata A, Munoz Jurado CM, Pina Mingorance I, Caravaca Hernandez MA, Vicente Garcia V, Ayala de la Pena F. Thrombosis and infections associated with PICC in onco-hematological patients, what is their relevance? Clin Transl Oncol. 2024 Dec;26(12):3226-3235. doi: 10.1007/s12094-024-03548-8. Epub 2024 Jun 12. PubMed PMID: 38865035.
AÑO: 2024; IF: 2.8
|
|
de la Morena-Barrio B, Palomo A, Padilla J, Martin-Fernandez L, Rojo-Carrillo JJ, Cifuentes R, Bravo-Perez C, Garrido-Rodriguez P, Minano A, Rubio AM, Pagan J, Llamas M, Vicente V, Vidal F, Lozano ML, Corral J, de la Morena-Barrio ME. Impact of genetic structural variants in factor XI deficiency: identification, accurate characterization, and inferred mechanism by long-read sequencing. J Thromb Haemost. 2023 Jul;21(7):1779-1788. doi: 10.1016/j.jtha.2023.03.009. Epub 2023 Mar 20. PubMed PMID: 36940803.
AÑO: 2023; IF: 5.5
|
|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|